Tipranavir

Tipranavir

SCHEMBL434955

CCC[C@@]1(CCc2ccccc2)CC(O)=C([C@H](CC)c2cccc(NS(=O)(=O)c3ccc(C(F)(F)F)cn3)c2)C(=O)O1.[NaH].[NaH]

nearest known ligand 0.99

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

pol

The experimentally established mechanism targets of Tipranavir. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MLNR O43193 1/20 0.99
NR1I2 O75469 1/20 0.99
ABCB11 O95342 1/20 0.99
PGR P06401 1/20 0.99
CTSD P07339 1/20 0.99
CHRM2 P08172 1/20 0.99
ADRA2A P08913 1/20 0.99
PGA5 P0DJD9 1/20 0.99
ADORA3 P0DMS8 1/20 0.99
CTSE P14091 1/20 0.99
GABRA1 P14867 1/20 0.99
ADRA2C P18825 1/20 0.99
DRD1 P21728 1/20 0.99
HTR2A P28223 1/20 0.99
AGTR1 P30556 1/20 0.99
CCKAR P32238 1/20 0.99
ADRA1A P35348 1/20 0.99
PTGS2 P35354 1/20 0.99
PPARG P37231 1/20 0.99
OPRD1 P41143 1/20 0.99

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Tipranavir SCHEMBL6953675 0.99 MLNR (1.00) MLNRNR1I2ABCB11PGRCTSD
Tipranavir SCHEMBL13536854 0.99 MLNR (1.00) MLNRNR1I2ABCB11PGRCTSD
Tipranavir SCHEMBL40629 0.99 MLNR (1.00) MLNRNR1I2ABCB11PGRCTSD
Tipranavir SCHEMBL5414762 0.99 MLNR (1.00) MLNRNR1I2ABCB11PGRCTSD
Tipranavir SCHEMBL6957763 0.99 MLNR (1.00) MLNRNR1I2ABCB11PGRCTSD
Tipranavir SCHEMBL7407890 0.99 MLNR (1.00) MLNRNR1I2ABCB11PGRCTSD
Tipranavir SCHEMBL29393318 0.99 MLNR (1.00) MLNRNR1I2ABCB11PGRCTSD
SCHEMBL7398499 0.97 MLNR (0.96) MLNRNR1I2ABCB11PGRCTSD
SCHEMBL7398500 0.97 MLNR (0.96) MLNRNR1I2ABCB11PGRCTSD
SCHEMBL7401866 0.97 MLNR (0.96) MLNRNR1I2ABCB11PGRCTSD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050042291-A1 Diffusion layer modulated solids HAWLEY MICHAEL (US) 2005-02-24 US claimed
WO-2012010617-A2 METHOD FOR IDENTIFYING INHIBITORS AGAINST CHIKUNGUNYA VIRUS TIBOTEC PHARMACEUTICALS (IE) 2012-01-26 WO disclosed
EP-1712231-A2 Method for improving the pharmacokinetics of tipranavir Pharmacia & Upjohn Company LLC (US) 2006-10-18 EP disclosed
EP-1643948-A1 DIFFUSION LAYER MODULATED SOLIDS Pharmacia & Upjohn Company LLC (US) 2006-04-12 EP disclosed
US-20050042291-A1 Diffusion layer modulated solids HAWLEY MICHAEL (US) 2005-02-24 US disclosed
WO-2005004763-A1 DIFFUSION LAYER MODULATED SOLIDS PHARMACIA & UPJOHN COMPANY LLC. (US) 2005-01-20 WO disclosed
CN-1154491-C Method for improving the pharmacokinetics of tipranavir 法玛西雅厄普约翰美国公司 2004-06-23 CN disclosed
CN-1324237-A Method for improving the pharmacokinetics of tipranavir UPJOHN CO (US) 2001-11-28 CN disclosed
EP-1126847-A1 METHOD FOR IMPROVING THE PHARMACOKINETICS OF TIPRANAVIR PHARMACIA & UPJOHN COMPANY (US) 2001-08-29 EP disclosed
US-6147095-A ADMINISTERING COMBINATION OF TIPRANAVIR AND RITONAVIR FOR TREATMENT OF HIV PHARMACIA & UPJOHN COMPANY (US) 2000-11-14 US disclosed
WO-2000025784-A1 METHOD FOR IMPROVING THE PHARMACOKINETICS OF TIPRANAVIR PHARMACIA & UPJOHN COMPANY (US) 2000-05-11 WO disclosed